Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 18/20 | 0.89 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.89 |
| ▸ | MMP2 | P08253 | 17/20 | 0.68 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803404 | 1.00 | ADAM10 (0.89) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL20323015 | 1.00 | ADAM10 (0.89) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL27651709 | 0.87 | ADAM10 (0.68) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL16406531 | 0.84 | ADAM10 (0.64) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL6336101 | 0.84 | ADAM10 (0.67) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL6336103 | 0.84 | ADAM10 (0.67) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL6344361 | 0.84 | ADAM10 (0.67) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL27651706 | 0.82 | ADAM10 (0.79) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL1364417 | 0.81 | ADAM10 (1.00) | ADAM10ERBB2MMP2MMP9MMP3 | |
| SCHEMBL1364081 | 0.81 | ADAM10 (1.00) | ADAM10ERBB2MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20180177901-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20150023873-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177901-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | MMP3, MMP1, TIMP3 | ADAM10 32/4885ERBB2 3763/4885MMP2 19/4885 |
| US-20150023873-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | MMP3, MMP1, TIMP3 | ADAM10 32/4885ERBB2 3763/4885MMP2 19/4885 |
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | MMP3, MMP1, TIMP3 | ADAM10 32/4885ERBB2 3763/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.